JTJack Wei Chieh Tan

Jack Wei Chieh Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jack Wei Chieh Tan has a total of 672 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of cardiovascular risk factors in a semi-urban population in Indonesia [Early detection of cardiovascular risk factors as primary prevention amongst North Sumatera adults (ECARDIA-NS) study]

    by Yasmine Fitrina Siregar, Paul Jie Wen Tern, Jingyi Lei, Kamal Kharrazi Ilyas, Abdul Halim Raynaldo, Yuke Sarastri, Teuku Bob Haykal, Cut Aryfa Andra, Faisal Habib, Refli Hasan, et al.

    Background: Controlling cardiovascular risk factors (CVRF) such as hypertension, dyslipidemia, diabetes, obesity and smoking has been shown to be effective in reducing the risk of developing cardiovascular diseases such as ischaemic heart disease and stroke. However, previous nationwide health surveys largely relied on surveys and interviews with only a limited subset of subjects undergoing formal testing with oral glucose tolerance tests and biochemical lipid profiling. Methods: This study aimed to provide an estimation of the prevalence of CVRFs in a population of adults in the province of North Sumatera. From March-December 2024, 1208 adults (80% female) aged 40 years and older with no apparent cardiovascular disease were opportunistically recruited from 15 screening sites in Kota Medan, Kota Tebing Tinggi and Kabupaten Langkat. Participants underwent anthropometric and blood pressure measurements, followed by a single lead electrocardiogram and blood draw for biochemical analysis of HbA1c and lipid panel. Subjects were surveyed regarding their demographics, medical history. A subset of participants was interviewed and scored on their knowledge, attitudes and practices (KAP) with a 14-point questionnaire. Results: Overall, 56% of the population had hypertension, 44% had dyslipidemia and 17% had diabetes. Most of these subjects were newly diagnosed based on measurements obtained during this screening study. 69% of participants were obese, a further 15% were overweight and 83% had elevated waist circumference. 1.3% of subjects had atrial fibrillation. Multivariable logistic regression showed significant associations between presence of CVRF and older age, obesity and elevated waist circumference. The median knowledge score was 5/10 and the median combined KAP score was 9/14. Further regression analysis suggested that KAP scores were associated with education level but not occupation. We also did not find any significant relationship between KAP score and presence of CVRFs. Conclusions: This community-based opportunistic screening study of 1208 adults in a semi-urban population in North Sumatera revealed a high burden of cardiometabolic disease as well as gaps in knowledge regarding CVRFs and how to control them. This suggests that still more work can be done in the region to address these.

  • Open Access

    Asian Pacific Society of Cardiology Consensus Statements on the Management of Iron Deficiency in Patients with Cardiovascular Disease

    by David Kheng Leng Sim, Shir Ying Lee, Tai-Chung Huang, Ju Le Tan, Kenny Yoong Kong Sin, Jason Choo, Robin Cherian, Julian Kenrick Xingyuan Loh, Paul S Myles, Jian Zhang, et al.

    Iron deficiency is a common, yet often untreated, comorbidity in patients with a wide range of cardiovascular disease (CVD). As clinical evidence mounts on the benefits of correction of iron deficiency in patients with CVD and the safety and efficacy of iron-replacement therapies, there is a need to elevate the quality of care provided to patients with CVD and iron deficiency in the Asia-Pacific region. Hence, the Asian Pacific Society of Cardiology established a multidisciplinary panel to develop regional consensus recommendations on the management of iron deficiency in patients with CVD. Twenty-three experts from various countries in the region reviewed the available clinical evidence to develop 21 consensus statements for patients with heart failure, cyanotic congenital heart disease, concomitant CVD or chronic kidney disease; those undergoing cardiac surgery or admitted to cardiovascular intensive care; or pregnant women with heart disease.

  • Understanding the cardiology training landscape in Asia-Pacific region

    by Fathima Aaysha Cader, Wei Yi Sean Lee, Wishnu Aditya Widodo, Raja Ezman Raja Shariff, Mohammed S Al-Omary, Gary Gan, Derek Pok Him Lee, Malis Vorn, Francis Lim, Amit Omprakash Singh, et al.

    Background: Considerable diversity in cardiology training and credentialing pathways exist within the Asia-Pacific. We aimed to map these variations and report similarities and disparities with a view to understanding needs in cardiology curricula development in the region. Methods: A 42-item online questionnaire was distributed to credentialed cardiologists serving as representatives from various regions within the Asia-Pacific, allowing obtainment of region-specific data as of December 2023. Responses were derived from a total of 23 regions. Results: All regions required specialist qualification to practise cardiology. Overall, 69.6% have a single training pathway, while 21.7% and 8.7% have two or three pathways, respectively. Majority (91.3%) had structured cardiology training curricula with assigned supervisor and regular assessments. The majority (91.3%) required mandatory training in internal medicine prior to cardiology. The total training duration inclusive of medicine and cardiology varied across regions (range 3–8 years) with 26.1% lasting 5 years and 43.5% lasting 6 years. All programmes had mandatory clinical cardiology training; 82.6% had interventional cardiology, 73.9% had electrophysiology, 73.9% had cardiac imaging training. However, 47.8% of regions had no training in cardiac computerized tomography (CT) and 56.5% had no cardiac magnetic resonance (CMR) imaging. 73.9% required mandatory research for board certification. In addition, 95.1% had an exit exam at completion of training (local in 95% cases). Board certification was mandatory for general cardiology practise in 69.6% of regions. Separate subspeciality fellowships were mandatory in 73.9% of regions. Conclusions: Significant regional variations in cardiology training and credentialing pathways exist, presenting opportunities to harmonize and improve training metrics regionally. Key message What is already known on the topic? Cardiology training within the Asia-Pacific region has considerable variation in terms of duration, curriculum, training, and exit requirements. What this study adds? This study outlines the similarities and differences of cardiology training between different countries within the Asia-Pacific region. How this study might affect research, practise or policy? Results from this study provide insights that may inform the development of harmonized and contextually appropriate cardiology curricula in the Asia-Pacific region. Establishing common standards for cardiology training could facilitate a more uniform and coherent curriculum across Asia, ensuring consistency in trainee competencies and clinical practise.

  • Open Access

    Asian Pacific Society of Cardiology Consensus Statements on the Use of Transcatheter Edge-to-Edge Repair in the Treatment of Tricuspid and Mitral Regurgitation

    by Khung Keong Yeo, David W.M. Muller, Jian’AN Wang, Shunsuke Kubo, Shih-Hsien Sung, Sai Satish, Krissada Meemook, Do-Yoon Kang, See Hooi Ewe, Alex Pui-Wai Lee, et al.


  • Open Access

    Asian Pacific Society of Cardiology Consensus Statements on the Use of Transcatheter Edge-to-edge Repair in the Treatment of Tricuspid and Mitral Regurgitation

    by Khung Keong Yeo, David Wm Muller, Jian’AN Wang, Shunsuke Kubo, Shih-Hsien Sung, Sai Satish, Krissada Meemook, Do-Yoon Kang, See Hooi Ewe, Alex Pui-Wai Lee, et al.

    Since the publication of the 2021 Asian Pacific Society of Cardiology (APSC) consensus statements on the use of MitraClip for mitral regurgitation (MR), other transcatheter edge-to-edge repair (TEER) devices have been introduced for the treatment of both tricuspid regurgitation (TR) and MR. Hence, the APSC developed these consensus recommendations, with general cardiologists and internal medicine specialists practising cardiology as the intended readers, to update the recommendations on the appropriate use of TEER in patients with TR or MR. The APSC expert panel reviewed and appraised the available evidence using the GRADE system. Consensus recommendations were developed and put to an online vote. Consensus was reached when at least 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 16 statements provide guidance for clinical practitioners in the region on the evaluation and management of patients with TR or MR in the Asia-Pacific region who are being considered for TEER therapy.

  • Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study

    by John P McCormick, Dirk De Bacquer, Catriona Jennings, Kornelia Kotseva, Guy De Backer, Iris Erlund, Sandra Ganly, Terhi Vihervaara, Gregory Y H Lip, Kausik K Ray, et al.

    Background Despite treatment, many hypertensive patients with coronary heart disease (CHD) have blood pressure (BP) that remains above guideline targets. However, less is known about patients in whom on-treatment BP is below target and major European guidelines differ substantially in their recommendations for such patients. Specifically, 2023 European Society of Hypertension (ESH) guidelines provide a Class 3 recommendation to proactively avoid BP below target whereas 2024 European Society of Cardiology (ESC) guidelines do not. Methods Between 2020 and 2023, adults hospitalised in the previous 6–24 months with incident or recurrent CHD were sampled in 14 countries from all six WHO regions and invited for a standardised interview and examination as part of the International Action on Secondary and Primary Prevention by Intervention to Reduce Events (INTERASPIRE) study. We measured seated BP twice using an automated oscillometric device after 5 min of rest. We defined participants as having BP above target (BP ≥130/80 mm Hg), at target (BP 120–129/70-79 mm Hg) or below target (Results Among 4548 participants (21.1% female), the mean age (±SD) was 60.0 (±10.3) years. At a median (IQR) of 1.05 (0.76–1.45) years after index CHD hospitalisation, 10.3% of patients had BP readings within the target range of 120–129/70-79 mm Hg, with 53.9% above target and 35.7% below target. Patients with below-target BP were more likely to have heart failure (13.6% vs 10.0%, p=0.041) and estimated glomerular filtration rate Conclusions More than one-third of INTERASPIRE patients with CHD presented with BP <120/70 mm Hg, which is below target per current European hypertension guidelines. Further research is needed in this population to resolve discordant guideline recommendations and determine whether de-escalation of BP-lowering therapies is beneficial or even harmful in this setting.


  • Top Cited Papers
    Open Access

    Analytical Performance Evaluation of the Cardiac Troponin T High Sensitivity Gen 6 Assay

    by Marko Knoll, Lori B Daniels, Christian Mueller, Nicholas L Mills, Evangelos Giannitsis, Alisa F A Rösser, Dunja Kurtoic, Annika Wahl, Richard Body, Robert H Christenson, et al.

    Background: High-sensitivity cardiac troponin (hs-cTn) assays are recommended for the diagnosis of acute myocardial infarction. Here, we characterize the analytical performance of a next-generation hs-cTn assay, Elecsys® Troponin T hs Gen 6 (Roche Diagnostics International). Methods: Surplus lithium-heparin plasma or serum samples from patients or healthy volunteers were run on Cobas® e 801, e 402, and Pro analyzers. Limits of blank (LoB), limits of detection (LoD), and limits of quantitation (LoQ) were determined according to CLSI EP17-A2, with target values of 1.0 and 1.5 ng/L for LoB/LoD and 3.0 ng/L (10% CV) and 1.5 ng/L (20% CV) for LoQ, respectively. Precision was measured, per CLSI EP17-A2, using 3 QC samples (approximately 4, 30, and 220 ng/L), 12 native samples, and 3 reagent lots. Linearity, per CLSI EP06-Ed2, was determined by diluting samples with cardiac troponin T (cTnT) concentration above the measuring range with a low/blank sample. Interference (per Glick) with endogenous and assay components at 5 cTnT concentrations was assessed. Results: Measured values for LoB, LoD, and LoQ at 10% and 20% CV were 0.1 to 0.7 ng/L, 0.3 to 1.4 ng/L, 1.0 to 2.9 ng/L, and 0.4 to 1.2 ng/L, respectively. Repeatability CVs were 1.0 to 5.8% for mean cTnT concentrations of 2.6 to 9230 ng/L in lithium-heparin plasma. High precision was shown across lots, and linearity was observed across the measuring range (1.5 to 9500 ng/L, all Pearson's r = 1.00). No interferences were observed, specified up to ≤1000 mg/dL hemoglobin, ≤50 mg/dL [≤855 µmol/L] icterus/bilirubin, and ≤1200 ng/mL biotin. Conclusions: The analytical performance characterization of the assay demonstrated high sensitivity, high precision at the low end and across the measuring range, and resistance to interference.


  • Top Cited Papers
    Open Access

    Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study

    by Lori B Daniels, Christian Mueller, Evangelos Giannitsis, Steven J R Meex, David Buehlmann, Peter Dilba, Garnet Bendig, Mette Cole, Richard Body, Robert H Christenson, et al.

    Background: Measurement of cardiac troponin (cTn) using high-sensitivity assays is recommended for the diagnosis of myocardial infarction. We determined sex-specific and uniform 99th percentile upper reference limits (URLs) using the new Elecsys® Troponin T high-sensitivity Gen 6 assay in a global, healthy reference range cohort. Methods: Lithium-heparin plasma and serum samples were prospectively collected from apparently healthy individuals aged ≥20 years across 34 global sites in the United States, Europe, China, and Japan. cTnT was measured using the Troponin T high-sensitivity Gen 6 assay on the Cobas® e 801 analyzer. Exclusion criteria were defined according to the 2022 IFCC guidance. Uniform and sex-specific 99th percentile URLs and nonparametric 95% CIs were determined in plasma and serum separately and combined. Results: The final study population comprised 4147 participants (52.5% female) with a median (25th–75th percentiles) age of 48.0 (33.0–59.0) years; 45.8%, 47.9%, 5.2%, and 1.1% were White, Asian, Black, and other/unknown, respectively. For sample matrices combined (n = 8294), 81.0% and 99.2% of cTnT values were above the limit of detection in females and males, respectively. Sex-specific 99th percentile URLs (95% CI) were 18 (16–23) ng/L for females and 32 (28–35) ng/L for males; the uniform 99th percentile URL was 27 (24–31) ng/L. URLs were comparable in plasma and serum samples. Conclusions: This study determined sex-specific and uniform 99th percentile URLs for the Troponin T high-sensitivity Gen 6 assay that were comparable irrespective of the matrix used in a large, global, healthy reference population.


  • Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial

    by Kenji Inoue, Raphael Twerenbold, Sazzli Kasim, Farina Mohd Salleh, Ahmad Suhailan Mohamed, Jack Wei Chieh Tan, Xin Yi Lim, Ting Boon Ping, Bakhtiar Ahmad, Alzamani Mohammad Idrose, et al.

    Background Rapid triage of patients presenting with chest pain is essential for early diagnosis and safe disposition. The European Society of Cardiology (ESC) 0/1-hour hs-cTn algorithm has shown promising performance in Western cohorts, but evidence supporting its implementation in diverse Asian emergency department (ED) settings remains limited. Therefore, we evaluated the safety and clinical utility of the ESC 0/1-hour algorithm for chest pain triage across multiple Asian EDs. Methods This was a prospective, stepped-wedge, cluster-randomised trial conducted across 12 hospitals in five Asian countries, enrolling 3869 patients with suspected acute coronary syndrome without ST elevation (NSTE-ACS). Usual care involved troponin testing without standardised timing, whereas the 0/1-hour protocol followed ESC recommendations using high-sensitivity cardiac troponin T testing at baseline and 1 hour. The primary endpoint was 30-day major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction (MI) and unplanned revascularisation. Non-inferiority was assessed using a one-sided 95% CI with a margin of 1.5%. Results Of 3869 patients (2059 usual care; 1810 0/1-hour care), MACE occurred in 1.7% of usual care patients and 1.4% in the 0/1-hour care (upper one-sided 95% CI –0.3%), confirming non-inferiority. ED discharge rates were significantly higher with the 0/1-hour algorithm (60% vs 35%, pConclusion The ESC 0/1-hour algorithm is safe and effective for rapid triage of chest pain in Asian EDs. These findings provide external validation of the 0/1-hour algorithm and support broader global implementation. Trial registration number UMIN000042461.


  • Open Access

    Asian Pacific Society of Cardiology Consensus Statements on the Management of Worsening Heart Failure

    by David Sim, Weiqin Lin, Louis Teo, Hawani Sasmaya Prameswari, Yee May Wong, Alexandre Mebazaa, Feras Bader, Andrew Sindone, Azmee Mohd Ghazi, Yuhui Zhang, et al.

    Heart failure (HF) patients in the Asia-Pacific region face multiple challenges with disease management, such as the suboptimal use of optimised medical therapy immediately after discharge and during the maintenance phase of treatment. Because recent evidence underscores the profound benefit of rapid uptitration of optimised medical therapy in HF patients upon discharge, there is a need to improve the quality of care provided to patients with worsening HF in the region. Hence, the Asian Pacific Society of Cardiology (APSC) developed these consensus recommendations, with general cardiologists and internal medicine specialists practising cardiology as the intended readers, to guide them in the appropriate evaluation and management of worsening HF. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 26 statements provide guidance for clinical practitioners in the Asia-Pacific region on the optimal management of worsening HF.